Under the agreement, Ventana will develop an in vitro diagnostic using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval. The target will be metastatic pancreatic cancer patients.
Data will demonstrate advances in research in a variety of cancer types, including melanoma,...
US Pharma M&A activity has yet to show any signs of a slowdown after the $8.1bn exit of Par...
Today, Novartis announced for the first time detailed results from its phase III EXPEDITION...
At a meeting today with analysts, Johnson & Johnson's Janssen Pharmaceuticals announced plans for regulatory approval of more than 10 new drugs between 2015 and 2019, each with the potential to generate at least $1B in sales, in addition to ...
Pfizer Inc. is trying to overcome the patent cliff that has seen its recent quarter results suffer by adopting its classic strategy of forging marketing alliances and making acquisitions. The pharma giant recently agreed to buy a stake in Dutch biotechnology company AM-Pharma....
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients.
Three years ago a jury found that a subsidiary, Janssen Pharmaceutical, committed Medicaid fraud and violated a state law in its labeling and marketing of Risperdal. A $1.2 billion fine was initially imposed on Johnson & Johnson.
Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. Patent No. 9,034,908, which pertains to the use of the bendamustine hydrochloride (HCl) formulation administered in a 50mL bag within ten minutes.
Pfizer Inc. today announced that it has received a request for additional information from the FTC with respect to its previously announced proposed acquisition of Hospira.
Dyadic International, Inc. is a global biotechnology company focused on enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries.
Eli Lilly and Company and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies.
ANI Pharmaceuticals has acquired the approved new drug application ("NDA") for a testosterone gel 1% product previously licensed to Teva Pharmaceuticals.
Pfizer recently announced their acquisition of a minority equity interest in AM-Pharma, and secured an exclusive option to acquire the remaining equity in the company.
Endo International has acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas.
New analysis finds that the market could reach $13.4 billion in 2019, due in part to advanced diagnosis capabilities.
BASF recently announced plans to sell several prominent pharmaceutical ingredients to Siegfried Holding AG for $306 million.
The California Supreme Court ruled that settlement agreements between pharmaceutical companies that keep cheaper, generic drugs off the market may be illegal if they include excessive cash payments.
The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of 2014.
Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets.
Now drug giant Johnson & Johnson is taking an unusual step, turning to independent bioethicists for advice.
Eli Lilly and Company today announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts.
Teva announced a voluntary recall of eight lots of Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) due to the potential presence of particulate matter.
The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium.
Innate Pharma SA today announced that it has signed a co-development and commercialization agreement with AstraZeneca to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody.
The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole).
Mylan N.V. today announced that it has increased its offer to acquire the issued and to be issued shares of Perrigo.
Merck easily beat Wall Street expectations despite first-quarter profit plunging 44 percent. The company was hurt by the sale of its consumer health business, unfavorable currency exchange rates and competition to some drugs.
Bristol-Myers Squibb reported results for the first quarter of 2015, which were highlighted by strong global sales for key brands, important regulatory and clinical milestones and the completion of several strategic transactions.
- Page 1